CO6341635A2 - Analogos de buprenorfina - Google Patents

Analogos de buprenorfina

Info

Publication number
CO6341635A2
CO6341635A2 CO11023774A CO11023774A CO6341635A2 CO 6341635 A2 CO6341635 A2 CO 6341635A2 CO 11023774 A CO11023774 A CO 11023774A CO 11023774 A CO11023774 A CO 11023774A CO 6341635 A2 CO6341635 A2 CO 6341635A2
Authority
CO
Colombia
Prior art keywords
formula
buprenorfine
analogs
present
orl
Prior art date
Application number
CO11023774A
Other languages
English (en)
Inventor
Donald J Kyle
Richard R Goehring
Marian E Fundytus
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of CO6341635A2 publication Critical patent/CO6341635A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención provee nuevos compuestos análogos de buprenorfina útiles para tratar una diversidad de condiciones, incluyendo el dolor, en particular dolor crónico. Más específicamente, la presente invención provee compuestos de las Fórmula I, Fórmula II o Fórmula III, que se muestran más adelante, y las sales, prodrogas y solvatos farmacéuticamente aceptables de lo mismo que exhiben afinidad por uno o más de los receptores opioides ORL-1, μ, δ, y/o κ.
CO11023774A 2008-07-30 2011-02-28 Analogos de buprenorfina CO6341635A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8476408P 2008-07-30 2008-07-30
US22611909P 2009-07-16 2009-07-16

Publications (1)

Publication Number Publication Date
CO6341635A2 true CO6341635A2 (es) 2011-11-21

Family

ID=41119539

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11023774A CO6341635A2 (es) 2008-07-30 2011-02-28 Analogos de buprenorfina

Country Status (25)

Country Link
US (1) US8530494B2 (es)
EP (2) EP2703404A1 (es)
JP (2) JP5525524B2 (es)
KR (1) KR101343395B1 (es)
CN (2) CN103450206A (es)
AU (1) AU2009277095B2 (es)
CA (1) CA2731939C (es)
CO (1) CO6341635A2 (es)
DK (1) DK2326651T3 (es)
ES (1) ES2449222T3 (es)
HK (1) HK1158622A1 (es)
HR (1) HRP20140182T1 (es)
IL (1) IL210391A0 (es)
ME (1) ME01665B (es)
MX (1) MX2011001268A (es)
NZ (1) NZ590650A (es)
PL (1) PL2326651T3 (es)
PT (1) PT2326651E (es)
RS (1) RS53154B (es)
RU (2) RU2520222C2 (es)
SI (1) SI2326651T1 (es)
SM (1) SMT201400023B (es)
UA (1) UA104004C2 (es)
WO (1) WO2010014229A1 (es)
ZA (1) ZA201100188B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012038813A1 (en) * 2010-09-21 2012-03-29 Purdue Pharma L.P. Buprenorphine analogs
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
US9096606B2 (en) 2011-12-08 2015-08-04 Purdue Pharma, L.P. Quarternized buprenorphine analogs
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
JP6317755B2 (ja) * 2012-12-07 2018-04-25 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド受容体モジュレーターとしてのブプレノルフィン類似体
US8987287B2 (en) 2012-12-14 2015-03-24 Purdue Pharma L.P. Spirocyclic morphinans and their use
ES2631197T3 (es) 2012-12-14 2017-08-29 Purdue Pharma Lp Análogos de piridonamorfinano y actividad biológica sobre los receptores opiodes
CA2896202A1 (en) * 2012-12-28 2014-07-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
US9056836B2 (en) 2013-01-31 2015-06-16 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
CA2934913A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
US9988392B2 (en) 2013-12-26 2018-06-05 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
EP3089982A4 (en) * 2013-12-26 2017-09-27 Purdue Pharma L.P. 7-beta analogs of orvinols
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
JP2017521373A (ja) * 2014-05-27 2017-08-03 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環モルフィナン及びその使用
MA40171A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1136214A (en) * 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US3474101A (en) * 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
NL289751A (es) 1962-03-02
GB1136764A (en) * 1965-08-13 1968-12-18 Reckitt & Sons Ltd Derivatives of thebaine and oripavine
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2230154A1 (de) 1972-06-21 1974-01-17 Boehringer Sohn Ingelheim N-(heteroaryl-methyl)-6,14-endoaetheno7alpha-hydroxyalkyl-tetrahydro-nororipavine und -thebaine, deren hydrierungsprodukte und saeureadditionssalze sowie verfahren zu deren herstellung
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PT95069B (pt) 1989-08-24 1997-10-31 Searle & Co Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5552406A (en) 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6136839A (en) 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
ATE276242T1 (de) 1997-05-30 2004-10-15 Banyu Pharma Co Ltd 2-oxoimidazol-derivate
WO1999048492A1 (fr) 1998-03-26 1999-09-30 Japan Tobacco Inc. Derives d'amide et antagonistes de nociceptine
JP2004538256A (ja) * 2001-03-02 2004-12-24 ユーロ−セルティーク，エス．エイ． Ｎ−ブト−３−エチル＝ノルブプレノルフィン及び使用方法
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
CN1939920B (zh) * 2005-09-29 2011-08-31 中国人民解放军军事医学科学院毒物药物研究所 东罂粟碱类化合物及其医药用途

Also Published As

Publication number Publication date
NZ590650A (en) 2013-01-25
RU2011107440A (ru) 2012-09-10
EP2326651A1 (en) 2011-06-01
WO2010014229A1 (en) 2010-02-04
SMT201400023B (it) 2014-05-07
PL2326651T3 (pl) 2014-05-30
JP5525524B2 (ja) 2014-06-18
JP2014208640A (ja) 2014-11-06
HRP20140182T1 (hr) 2014-04-11
PT2326651E (pt) 2014-02-12
AU2009277095B2 (en) 2012-09-06
SI2326651T1 (sl) 2014-03-31
DK2326651T3 (da) 2014-01-20
KR101343395B1 (ko) 2013-12-19
IL210391A0 (en) 2011-03-31
RU2013106944A (ru) 2014-08-27
UA104004C2 (uk) 2013-12-25
ES2449222T3 (es) 2014-03-18
AU2009277095A1 (en) 2010-02-04
ZA201100188B (en) 2011-09-28
ME01665B (me) 2014-09-20
US20110136846A1 (en) 2011-06-09
HK1158622A1 (en) 2012-07-20
US8530494B2 (en) 2013-09-10
RS53154B (en) 2014-06-30
CN102112479B (zh) 2014-10-29
CA2731939C (en) 2017-05-23
CN102112479A (zh) 2011-06-29
EP2326651B1 (en) 2013-11-27
KR20110036859A (ko) 2011-04-11
RU2520222C2 (ru) 2014-06-20
JP2012506839A (ja) 2012-03-22
CN103450206A (zh) 2013-12-18
CA2731939A1 (en) 2010-02-04
EP2703404A1 (en) 2014-03-05
MX2011001268A (es) 2011-07-29

Similar Documents

Publication Publication Date Title
CO6341635A2 (es) Analogos de buprenorfina
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
CU20110235A7 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CO6290683A2 (es) Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met
CR20140413A (es) Inhibidores de serina/treonina cinasa
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
DOP2012000149A (es) Compuestos triciclicos novedosos
ECSP088970A (es) Amino-imidazolonas y su uso como medicamento para el tratamiento de la deficiencia cognitiva, la enfermedad de alzheimer, la neurodegeneración y la demencia
ECSP099723A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer
UY31083A1 (es) Derivados de sulfoximinas para la inhibicion de b-secretasa
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
ECSP088972A (es) Isoindoles sustituidos como inhibidores de bace y su uso
ECSP088306A (es) Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr
NI200900170A (es) Derivados de isoindolina 4' - o - sustituidos y composiciones que los comprenden y métodos para usar los mismos.
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
AR047992A1 (es) Diaminopirimidinas como antagonistas de p2x3 y p2x2/3
CL2009001059A1 (es) Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
NI201200132A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos
NI200900031A (es) Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos.
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
UY31084A1 (es) Compuestos de azaindol para la inhibicion de b-secretasa
DOP2011000196A (es) Compuestos purina

Legal Events

Date Code Title Description
FC Application refused